Qualigen Therapeutics, Inc.

We are grateful for the support of our employees, partners, investigators, patients and families who are all working together to advance new treatments for challenging diseases. We can't do it without you. Wishing everyone the best this Holiday Season. #driventodeliver #oncology

Every moment counts for the nearly 100,000 people in the US living with pancreatic cancer. We are proud to obtain Orphan Drug Designation from the FDA for QN-302 toward a potential treatment for pancreatic cancer. Learn about World Pancreatic Cancer Day: shorturl.at/BZ145

We initiated dosing of three patients in our first cohort for our Phase 1a clinical trial. Read about our progress in our Third Quarter To Date Corporate Update: shorturl.at/oyFOX #driventodeliver #oncology

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors #driventodeliver #oncology #clinicaltrials shorturl.at/jnQ38

Qualigen Therapeutics is attending the BIO Investor Forum Oct 17th-18th in San Francisco. Our Chief Medical Officer Tariq Arshad will be giving a presentation at 2pm PT tomorrow. Please join us! bif.bio.org

Our Chief Medical Officer Dr. Tariq Arshad presented two posters on potential clinical #biomarkers and transcriptomic data associated with QN-302’s mechanism of action at the AACR Special Conference: Pancreatic Cancer in Boston! #oncology #driventodeliver shorturl.at/jktMY

Our Chief Medical Officer Dr. Tariq Arshad is attending the 5th Annual RAS-Targeted Drug Development Summit held Sept 26-28th in Boston. Our goal is to develop effective therapies for RAS-driven cancers, which make up ~25% of all cancers #oncology shorturl.at/glqtN

We are excited to continue our partnership with @TD2_Oncology on our Phase 1 clinical trial for QN-302. We anticipate to enroll our first patient in the second half of 2023. #oncology #phase1

We are excited to be an important partner with Qualigen Therapeutics in their Phase I clinical development. Moving new therapies to the patients who need it the most. #oncology #drugdevelopment hubs.li/Q01_tmcd0

Qualigen Therapeutics, Inc. Reports Financial Results and Provides Corporate Update #driventodeliver #oncology #ClinicalTrials ir.qualigeninc.com/full-news/?qm-…

Listen to our SVP and Chief Medical Officer Tariq Arshad discuss the promise of pan-RAS inhibitors as an approach to potentially treat multiple types of RAS-driven cancers, on the "Empowered Patient Podcast" #driventodeliver #oncology @KarenJagoda shorturl.at/ioqAF

A tumour-busting drug developed at UCL @School_Pharmacy, with backing from UCLTF, is set to be trialled in patients following U.S regulatory approval. @AlbionVC @UCL_Business @QualigenInc Discover more: bit.ly/3QsTKSp

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors. #oncology #clinicaldevelopment #driventodeliver ir.qualigeninc.com/full-news/?qm-…

All cash deal for FastPack® diagnostics business solidifies and supports Qualigen’s strategic priority on therapeutics. #driventodeliver #oncology ir.qualigeninc.com/full-news/?qm-…

Qualigen Therapeutics delegates @DrewHertig and @drtariqarshad1 are looking forward to connecting in 1:1 partnering at BIO International Convention in Boston this week! #StandUpForScience #BIO2023

A snapshot from #asco2023 this morning where Qualigen Therapeutics Chief Medical Officer, Dr. Tariq Arshad presented data on our Pan-RAS platform. bit.ly/3CcAPCY #oncology #pancreaticcancer #cancerresearch #ras

Join us @ASCO. 8-11am in Hall A. Learn about Qualigen’s Pan-RAS platform. Here is some info on our posters and presentations. bit.ly/42g7AcU bit.ly/40Jc37d bit.ly/41Ip2Hv #ASCO23 #oncology #pancreaticcancer #breastcancer #cancerresearch #ras

Dr. Stephen Neidle, UCL Professor and QN-302 inventor, presented yesterday at the London Pancreas Workshop 2023, which focused on pancreatic cancer research. Dr. Neidle has played a key role in the progress of the QN-302 program. #pancreaticcancer #oncology

Dr. Tariq Arshad and Dr. Stephen Neidle ready to present data on G4-Selective Transcription Inhibitor #QN-302 as a potential treatment for pancreatic cancer during @AACR in Orlando. bit.ly/3LdRU4H #driventodeliver #oncology #AACR2023

Learn about Orphan Drug Designation (ODD) and QN-302, a G-Quadruplex (G4) transcription inhibitor for the intended indication of pancreatic cancer. bit.ly/3Ej6zHQ #orphandrug #driventodeliver #cancerresearch #pancreaticcancer.